
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/660802/publications.pdf Version: 2024-02-01



YING JUNG

#	Article	IF	CITATIONS
1	Management of enterococcal central line-associated bloodstream infections in patients with cancer. BMC Infectious Diseases, 2021, 21, 643.	2.9	6
2	Improving the safety of outpatient parenteral antimicrobial therapy for patients with solid tumors. Supportive Care in Cancer, 2021, , 1.	2.2	0
3	Infectious complications among patients with AML treated with immune checkpoint inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	3
4	Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. Seminars in Oncology, 2020, 47, 165-167.	2.2	0
5	INTERNATIONAL MULTICENTER EXPERIENCE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN IMMUNOCOMPROMISED CANCER PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019003.	1.3	0
6	Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species?. Medical Mycology, 2019, 57, 639-642.	0.7	1
7	Unnecessary Removal of Central Venous Catheters in Cancer Patients with Bloodstream Infections. Infection Control and Hospital Epidemiology, 2018, 39, 222-225.	1.8	8
8	359. Baseline Serum <i>Aspergillus</i> Galactomannan Index Among <i>Aspergillus</i> Species in Hematologic Malignancies Patients With Invasive Pulmonary Aspergillosis. Open Forum Infectious Diseases, 2018, 5, S141-S141.	0.9	0
9	Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies. BMC Infectious Diseases, 2018, 18, 656.	2.9	13
10	Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes. Annals of Medicine, 2018, 50, 713-720.	3.8	16
11	Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. Mycoses, 2018, 61, 861-867.	4.0	14
12	Improvement in the diagnosis of catheter-related bloodstream infections in a tertiary cancer center. American Journal of Infection Control, 2017, 45, e34-e39.	2.3	6
13	A Novel Nonantibiotic Nitroglycerin-Based Catheter Lock Solution for Prevention of Intraluminal Central Venous Catheter Infections in Cancer Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
14	Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000–2016): Uncommon, with improved survival but still deadly often. Journal of Infection, 2017, 75, 572-580.	3.3	30
15	The influence of using antibiotic-coated peripherally inserted central catheters on decreasing the risk of central line-associated bloodstream infections. American Journal of Infection Control, 2016, 44, 1037-1040.	2.3	14
16	A clinical practical approach to the surveillance definition of central line–associated bloodstream infection in cancer patients with mucosal barrier injury. American Journal of Infection Control, 2016, 44, 931-934.	2.3	23
17	Successful Salvage of Central Venous Catheters in Patients with Catheter-Related or Central Line-Associated Bloodstream Infections by Using a Catheter Lock Solution Consisting of Minocycline, EDTA, and 25% Ethanol. Antimicrobial Agents and Chemotherapy, 2016, 60, 3426-3432.	3.2	38
18	Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer. Antimicrobial Agents and Chemotherapy, 2016, 60, 239-244.	3.2	8

#	Article	IF	CITATIONS
19	Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection. PLoS ONE, 2015, 10, e0130999.	2.5	34
20	Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. International Journal of Antimicrobial Agents, 2015, 45, 283-288.	2.5	45
21	<i>In Vivo</i> Biocompatibility and <i>In Vitro</i> Efficacy of Antimicrobial Gendine-Coated Central Catheters. Antimicrobial Agents and Chemotherapy, 2015, 59, 5611-5618.	3.2	10
22	Prevention of Transmission of Multidrug-Resistant Organisms during Catheter Exchange using Antimicrobial Catheters. Antimicrobial Agents and Chemotherapy, 2014, 58, 5291-5296.	3.2	15
23	Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 3148-3155.	3.0	52
24	Insights on the Role of Antimicrobial Cuffed Endotracheal Tubes in Preventing Transtracheal Transmission of VAP Pathogens from an <i>In Vitro</i> Model of Microaspiration and Microbial Proliferation. BioMed Research International, 2014, 2014, 1-11.	1.9	1
25	The use of minocycline-rifampin coated central venous catheters for exchange of catheters in the setting of staphylococcus aureus central line associated bloodstream infections. BMC Infectious Diseases, 2014, 14, 518.	2.9	15
26	Disposable gendine antimicrobial gloves for preventing transmission of pathogens in health care settings. American Journal of Infection Control, 2014, 42, 55-59.	2.3	16
27	Can procalcitonin differentiate Staphylococcus aureus from coagulase-negative staphylococci in clustered gram-positive bacteremia?. Diagnostic Microbiology and Infectious Disease, 2013, 76, 158-161.	1.8	12
28	Glyceryl Trinitrate Complements Citrate and Ethanol in a Novel Antimicrobial Catheter Lock Solution To Eradicate Biofilm Organisms. Antimicrobial Agents and Chemotherapy, 2013, 57, 3555-3560.	3.2	38
29	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. Journal of Antimicrobial Chemotherapy, 2013, 68, 1872-1880.	3.0	125
30	Improved Antibiotic-Impregnated Catheters with Extended-Spectrum Activity against Resistant Bacteria and Fungi. Antimicrobial Agents and Chemotherapy, 2012, 56, 935-941.	3.2	73
31	Hospital environment and invasive aspergillosis in patients with hematologic malignancy. American Journal of Infection Control, 2012, 40, 247-249.	2.3	27
32	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1835-1844.	2.0	227
33	Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. Journal of Infection, 2012, 64, 68-75.	3.3	124
34	Rhodococcus Bacteremia in Cancer Patients Is Mostly Catheter Related and Associated with Biofilm Formation. PLoS ONE, 2012, 7, e32945.	2.5	35
35	Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1169-1175.	2.0	44
36	Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibiotic-impregnated catheters: More than 0.5 million catheter days and 7 years of clinical experience*. Critical Care Medicine, 2011, 39, 245-251.	0.9	75

#	Article	IF	CITATIONS
37	Novel approach using antimicrobial catheters to improve the management of central lineâ€associated bloodstream infections in cancer patients. Cancer, 2011, 117, 2551-2558.	4.1	25
38	The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. Biomaterials, 2011, 32, 2689-2694.	11.4	54
39	Outcome Analysis of Invasive Aspergillosis in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients: The Role of Novel Antimold Azoles. Oncologist, 2011, 16, 1049-1060.	3.7	46
40	Panton Valentine Leukocidin Exotoxin Has No Effect on the Outcome of Cancer Patients With Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. Medicine (United States), 2011, 90, 312-318.	1.0	11
41	Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. American Journal of Blood Research, 2011, 1, 98-105.	0.6	22
42	Perils of quinolone exposure in cancer patients. Cancer, 2010, 116, 967-973.	4.1	94
43	Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?. Cancer, 2010, 116, 5290-5296.	4.1	35
44	Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization. Journal of Antimicrobial Chemotherapy, 2010, 65, 2001-2004.	3.0	45
45	Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. International Journal of Antimicrobial Agents, 2010, 36, 182-186.	2.5	39
46	Utility of Galactomannan Enzyme Immunoassay and (1,3) β- <scp>d</scp> -Glucan in Diagnosis of Invasive Fungal Infections: Low Sensitivity for <i>Aspergillus fumigatus</i> Infection in Hematologic Malignancy Patients. Journal of Clinical Microbiology, 2009, 47, 129-133.	3.9	165
47	Differentiating Culture Samples Representing Coagulase-Negative Staphylococcal Bacteremia from Those Representing Contamination by Use of Time-to-Positivity and Quantitative Blood Culture Methods. Journal of Clinical Microbiology, 2009, 47, 3255-3260.	3.9	62
48	Novel Antiseptic Urinary Catheters for Prevention of Urinary Tract Infections: Correlation of In Vivo and In Vitro Test Results. Antimicrobial Agents and Chemotherapy, 2009, 53, 5145-5149.	3.2	78
49	Management of the Catheter in Documented Catheterâ€Related Coagulaseâ€Negative Staphylococcal Bacteremia: Remove or Retain?. Clinical Infectious Diseases, 2009, 49, 1187-1194.	5.8	82
50	Efficacy of novel antimicrobial gloves impregnated with antiseptic dyes in preventing the adherence of multidrug-resistant nosocomial pathogens. American Journal of Infection Control, 2009, 37, 294-300.	2.3	27
51	Multidrug-resistant Escherichia coli bacteremia in cancer patients. American Journal of Infection Control, 2009, 37, 741-745.	2.3	23
52	The Crucial Role of Catheters in Micrococcal Bloodstream Infections in Cancer Patients. Infection Control and Hospital Epidemiology, 2009, 30, 83-85.	1.8	20
53	Tigecycline Use in Cancer Patients With Serious Infections. Medicine (United States), 2009, 88, 211-220.	1.0	45
54	Management of Bacillus Bacteremia. Medicine (United States), 2009, 88, 279-283.	1.0	34

#	Article	IF	CITATIONS
55	The changing epidemiology of invasive candidiasis. Cancer, 2008, 112, 2493-2499.	4.1	321
56	Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia, 2008, 22, 496-503.	7.2	71
57	Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. International Journal of Antimicrobial Agents, 2008, 32, 515-518.	2.5	57
58	The role of chelators in preventing biofilm formation and catheter-related bloodstream infections. Current Opinion in Infectious Diseases, 2008, 21, 385-392.	3.1	100
59	Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant <i>Staphylococcus</i> Bacteremic Isolates Embedded in Biofilm. Antimicrobial Agents and Chemotherapy, 2007, 51, 1656-1660.	3.2	340
60	Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica, 2007, 92, 1216-1223.	3.5	55
61	Colistin Is Effective in Treatment of Infections Caused by Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in Cancer Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 1905-1911.	3.2	110
62	Risk of Bioaerosol Contamination With <i>Aspergillus</i> Species Before and After Cleaning in Rooms Filtered With High-Efficiency Particulate Air Filters That House Patients With Hematologic Malignancy. Infection Control and Hospital Epidemiology, 2007, 28, 1066-1070.	1.8	22
63	Risk factors for infections with multidrug-resistantStenotrophomonas maltophilia in patients with cancer. Cancer, 2007, 109, 2615-2622.	4.1	53
64	Functional Analysis and Regulation of the Divergent spuABCDEFGH-spul Operons for Polyamine Uptake and Utilization in Pseudomonas aeruginosa PAO1. Journal of Bacteriology, 2002, 184, 3765-3773.	2.2	93
65	Molecular Characterization and Regulation of the aguBA Operon, Responsible for Agmatine Utilization in Pseudomonas aeruginosa PAO1. Journal of Bacteriology, 2001, 183, 6517-6524.	2.2	66